Skip to content

Empagliflozin and Metformin

Brand name: Synjardy

Empagliflozin and Metformin comes in 14 pill versions in our database, in 10 strengths, from 2 manufacturers. Check the imprint to tell them apart.

Empagliflozin and Metformin pill images

5 mg / 500 mg 1 pill

5 mg / 850 mg 1 pill

5 mg / 1000 mg 2 pills

10 mg / 1000 mg 1 pill

12.5 mg / 500 mg 2 pills

12.5 mg / 1000 mg 3 pills

25 mg / 1000 mg 1 pill

500 mg / 5 mg 1 pill

850 mg / 12.5 mg 1 pill

1000 mg / 5 mg 1 pill

What is Empagliflozin and Metformin used for?

Empagliflozin and Metformin is used for type 2 diabetes.

Medicine type
Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label

SYNJARDY

SYNJARDY is a combination of empagliflozin and metformin hydrochloride (HCl) immediate-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

SYNJARDY XR

SYNJARDY XR is a combination of empagliflozin and metformin HCl extended-release indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin

Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:

  • Cardiovascular (CV) death in adults with established CV disease.
  • CV death and hospitalization for heart failure in adults with heart failure.
  • Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression.

Limitations of Use

  • SYNJARDY and SYNJARDY XR are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.
  • Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications.
  • Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations.

From the FDA-approved label on DailyMed (published Aug 27, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.